Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefano Rusconi

Showing results (151-160 of 192) with videos related to

Pageof 20
Sort By:
Journal of Medical Virology|August 11, 2020
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort studyAndrea Giacomelli, Gabriele Pagani, Anna L Ridolfo, et al.
BMJ Open|February 10, 2024
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitorsTommaso Clemente, Laura Galli, Riccardo Lolatto, et al.
Nature Communications|May 26, 2011
A novel methodology for large-scale phylogeny partitionMattia C F Prosperi, Massimo Ciccozzi, Iuri Fanti, et al.
JMIR Public Health and Surveillance|July 11, 2020
Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOVID19 Web-Based SurveyFulvio Adorni, Federica Prinelli, Fabrizio Bianchi, et al.
International Journal of Antimicrobial Agents|November 17, 2025
Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimensFrancesca Lombardi, Elio Gentilini Cacciola, Federica Carli, et al.
Journal of the International AIDS Society|November 15, 2014
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trialMassimiliano Fabbiani, Simona Di Giambenedetto, Eugenia Quiros-Roldan, et al.
Plos One|June 21, 2017
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) projectNicola Squillace, Elena Ricci, Tiziana Quirino, et al.
The Journal of Antimicrobial Chemotherapy|October 13, 2019
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort studySara Modica, David Redi, Roberta Gagliardini, et al.
The Journal of Antimicrobial Chemotherapy|January 18, 2017
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Massimiliano Fabbiani, Eugenia Quiros Roldan, et al.
BMJ Open|December 5, 2019
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)Arturo Ciccullo, Gianmaria Baldin, Amedeo Capetti, et al.
Pageof 20

Showing results (151-160 of 192) with videos related to

Sort By:
Pageof 20
Journal of Medical Virology|August 11, 2020
Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: A retrospective cohort studyAndrea Giacomelli, Gabriele Pagani, Anna L Ridolfo, et al.
BMJ Open|February 10, 2024
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitorsTommaso Clemente, Laura Galli, Riccardo Lolatto, et al.
Nature Communications|May 26, 2011
A novel methodology for large-scale phylogeny partitionMattia C F Prosperi, Massimo Ciccozzi, Iuri Fanti, et al.
JMIR Public Health and Surveillance|July 11, 2020
Self-Reported Symptoms of SARS-CoV-2 Infection in a Nonhospitalized Population in Italy: Cross-Sectional Study of the EPICOVID19 Web-Based SurveyFulvio Adorni, Federica Prinelli, Fabrizio Bianchi, et al.
International Journal of Antimicrobial Agents|November 17, 2025
Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimensFrancesca Lombardi, Elio Gentilini Cacciola, Federica Carli, et al.
Journal of the International AIDS Society|November 15, 2014
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trialMassimiliano Fabbiani, Simona Di Giambenedetto, Eugenia Quiros-Roldan, et al.
Plos One|June 21, 2017
Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) projectNicola Squillace, Elena Ricci, Tiziana Quirino, et al.
The Journal of Antimicrobial Chemotherapy|October 13, 2019
Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort studySara Modica, David Redi, Roberta Gagliardini, et al.
The Journal of Antimicrobial Chemotherapy|January 18, 2017
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)Simona Di Giambenedetto, Massimiliano Fabbiani, Eugenia Quiros Roldan, et al.
BMJ Open|December 5, 2019
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)Arturo Ciccullo, Gianmaria Baldin, Amedeo Capetti, et al.
Pageof 20